메뉴 건너뛰기




Volumn 2, Issue 2, 2015, Pages 41-45

Facts and numbers on epidemiology and pharmacological treatment of heart failure with preserved ejection fraction

Author keywords

diastolic; heart failure with preserved ejection fraction; Treatment

Indexed keywords


EID: 84983193548     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12037     Document Type: Editorial
Times cited : (14)

References (20)
  • 2
    • 33746088001 scopus 로고    scopus 로고
    • Trends in prevalence and outcome of heart failure with preserved ejection fraction
    • Owan TE, Hodge Do, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251–259.
    • (2006) N Engl J Med , vol.355 , pp. 251-259
    • Owan, T.E.1    Do, H.2    Herges, R.M.3    Jacobsen, S.J.4    Roger, V.L.5    Redfield, M.M.6
  • 4
    • 84880118241 scopus 로고    scopus 로고
    • The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis
    • Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 2012; 33: 1750–1757.
    • (2012) Eur Heart J , vol.33 , pp. 1750-1757
  • 5
    • 84874357580 scopus 로고    scopus 로고
    • Defining diastolic heart failure and identifying effective therapies
    • Cleland JG, Pellicori P. Defining diastolic heart failure and identifying effective therapies. JAMA. 2013 Feb 27; 309(8): 825–6.
    • (2013) JAMA , vol.309 , Issue.8 , pp. 825-826
    • Cleland, J.G.1    Pellicori, P.2
  • 7
    • 84856203229 scopus 로고    scopus 로고
    • Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study
    • Conraads VM, Metra M, Kamp O, De Keulenaer GW, Pieske B, Zamorano J, Vardas PE, Böhm M, Dei Cas L. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012; 14: 219–225.
    • (2012) Eur J Heart Fail , vol.14 , pp. 219-225
    • Conraads, V.M.1    Metra, M.2    Kamp, O.3    De Keulenaer, G.W.4    Pieske, B.5    Zamorano, J.6    Vardas, P.E.7    Böhm, M.8    Dei, C.L.9
  • 8
    • 0025129567 scopus 로고
    • Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance
    • Setaro JF, Zaret BL, Schulman DS, Black HR, Soufer R. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance. Am J Cardiol 1990; 66: 981–986.
    • (1990) Am J Cardiol , vol.66 , pp. 981-986
    • Setaro, J.F.1    Zaret, B.L.2    Schulman, D.S.3    Black, H.R.4    Soufer, R.5
  • 9
    • 84885004398 scopus 로고    scopus 로고
    • Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial
    • Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 2013; 62: 1330–1338.
    • (2013) J Am Coll Cardiol , vol.62 , pp. 1330-1338
    • Kosmala, W.1    Holland, D.J.2    Rojek, A.3    Wright, L.4    Przewlocka-Kosmala, M.5    Marwick, T.H.6
  • 12
    • 0041408234 scopus 로고    scopus 로고
    • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial
    • Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet 2003; 362: 777–781.
    • (2003) Lancet , vol.362 , pp. 777-781
    • Yusuf, S.1    Pfeffer, M.A.2    Swedberg, K.3    Granger, C.B.4    Held, P.5    McMurray, J.J.6    Michelson, E.L.7    Olofsson, B.8    Ostergren, J.9
  • 14
    • 84867745957 scopus 로고    scopus 로고
    • Prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
    • Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ. Prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction (PARAMOUNT) investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012; 380: 1387–1395.
    • (2012) Lancet , vol.380 , pp. 1387-1395
    • Solomon, S.D.1    Zile, M.2    Pieske, B.3    Voors, A.4    Shah, A.5    Kraigher-Krainer, E.6    Shi, V.7    Bransford, T.8    Takeuchi, M.9    Gong, J.10    Lefkowitz, M.11    Packer, M.12    McMurray, J.J.13
  • 17
    • 79960396933 scopus 로고    scopus 로고
    • Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study
    • Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011; 124: 164–174.
    • (2011) Circulation , vol.124 , pp. 164-174
    • Guazzi, M.1    Vicenzi, M.2    Arena, R.3    Guazzi, M.D.4
  • 19
    • 84899575590 scopus 로고    scopus 로고
    • Acute hemodynamic effects or rIociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized double-blind, placebo-controlled, single-dose study
    • Amsterdam, (10 January 2005).
    • Bondermann D, Pretsch I, Steringer-Mascherbauer R, Rosenkranz S, Tufaro C, Frey R, Ochan M, Kilama S, Unger S, Roessig L, Lang IM. Acute hemodynamic effects or rIociguat in patients with pulmonary hypertension associated with diastolic heart failure (DILATE-1): a randomized double-blind, placebo-controlled, single-dose study. Eur Heart J, Abstract 3321 ESC Amsterdam 2013. doi:10.1093/eurheartj/ehi115 (10 January 2005).
    • (2013) Eur Heart J
    • Bondermann, D.1    Pretsch, I.2    Steringer-Mascherbauer, R.3    Rosenkranz, S.4    Tufaro, C.5    Frey, R.6    Ochan, M.7    Kilama, S.8    Unger, S.9    Roessig, L.10    Lang, I.M.11
  • 20
    • 84876400116 scopus 로고    scopus 로고
    • Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of- concept study
    • Maier LS, Layug B, Karwatowska E. Ranolazine for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of- concept study. J Am Coll Cardiol Heart Failure 2013; 1: 115–122.
    • (2013) J Am Coll Cardiol Heart Failure , vol.1 , pp. 115-122
    • Maier, L.S.1    Layug, B.2    Karwatowska, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.